세계의 대사체학 기술 시장 규모 조사 : 제품별, 적응증별, 용도별, 지역별 예측(2022-2032년)

Global Metabolomics Technologies Market is valued at approximately USD 14.50 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 13.1% over the forecast period 2024-2032. The field of metabolomics encompasses the comprehensive analysis of metabolites within biological systems, aiming to provide a holistic understanding of metabolic processes. This burgeoning market is driven by several pivotal factors, including rapid technological advancements, increasing healthcare expenditure, and the expanding applications of metabolomics across various industries. Metabolomics technologies offer profound insights into metabolic perturbations caused by infections and diseases, providing direct signatures of disease onset and potential therapeutic targets.

The rising healthcare expenditure globally underscores the growing emphasis on advanced diagnostic and therapeutic solutions, wherein metabolomics plays a crucial role. With technological advancements, sophisticated bioinformatics platforms have emerged, facilitating seamless data processing and interpretation, thus propelling the adoption of metabolomics in drug discovery, biomarker discovery, and precision medicine. For instance, a surge in pharmaceutical and biotech R&D, coupled with substantial government and private funding, has bolstered the growth of this market. However, the market faces significant challenges, such as the high cost of instruments and services, complexity in data analysis, and issues related to standardization and quality control. Despite these hurdles, the opportunities in precision medicine, drug discovery, and nutritional profiling present lucrative prospects for market expansion. Furthermore, the non-invasive nature of metabolomics makes it an ideal tool for various applications, including agriculture, pharmaceuticals, and preventive healthcare.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. The North American region is expected to dominate the market during the forecast period, attributed to the availability of advanced technologies, significant investments in metabolomics research, and a strong focus on personalized medicine and cancer therapeutics. Conversely, the Asia-Pacific region is projected to witness the fastest growth rate due to the high prevalence of cancer, unmet healthcare needs, and substantial investments in R&D for cancer drug discovery and personalized medicine.

Major market players included in this report are:

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Bruker
• Danaher Corp.
• Merck KGaA
• Shimadzu Corp.
• Thermo Fisher Scientific Inc.
• Waters Corp.
• Biocrates Life Sciences AG
• Creative Proteomics
• Owl Metabolomics
• Metabolomic Discoveries GmbH
• Numares AG
• Metabolon, Inc.
• Chenomx Inc.

The detailed segments and sub-segment of the market are explained below:

By Product:

• Separation Techniques
• Detection Techniques

By Indication:

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Inborn Errors of Metabolism
• Other Diseases Indication

By Application:

• Biomarker Discovery
• Drug Discovery
• Toxicology Testing
• Nutrigenomics
• Functional Genomics
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Metabolomics Technologies Market Executive Summary

• 1.1. Global Metabolomics Technologies Market Size & Forecast (2022-2032 )
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Product
  • 1.3.2. By Indication
  • 1.3.3. By Application
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Metabolomics Technologies Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Metabolomics Technologies Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Technological Advancements
  • 3.1.2. Increasing Healthcare Expenditure
  • 3.1.3. Expanding Applications Across Industries
• 3.2. Market Restraints
  • 3.2.1. High Cost of Instruments and Services
  • 3.2.2. Complexity of Data Analysis
  • 3.2.3. Standardization and Quality Control Challenges
  • 3.2.4. Limited Biomarker Validation and Clinical Utility
• 3.3. Market Opportunities
  • 3.3.1. Precision Medicine and Personalized Healthcare
  • 3.3.2. Drug Discovery and Development

Chapter 4. Global Metabolomics Technologies Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Metabolomics Technologies Market Size & Forecasts by Product 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Metabolomics Technologies Market: Product Revenue Trend Analysis, 2024 & 2029 (USD Billion)
  • 5.2.1. Separation Techniques
  • 5.2.2. Detection Techniques

Chapter 6. Global Metabolomics Technologies Market Size & Forecasts by Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Metabolomics Technologies Market: Indication Revenue Trend Analysis, 2024 & 2029 (USD Billion)
  • 6.2.1. Cancer
  • 6.2.2. Cardiovascular Disorders
  • 6.2.3. Neurological Disorders
  • 6.2.4. Inborn Errors of Metabolism
  • 6.2.5. Other Diseases Indication

Chapter 7. Global Metabolomics Technologies Market Size & Forecasts by Application 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Metabolomics Technologies Market: Application Revenue Trend Analysis, 2024 & 2029 (USD Billion)
  • 7.2.1. Biomarker Discovery
  • 7.2.2. Drug Discovery
  • 7.2.3. Toxicology Testing
  • 7.2.4. Nutrigenomics
  • 7.2.5. Functional Genomics
  • 7.2.6. Others

Chapter 8. Global Metabolomics Technologies Market Size & Forecasts by Region 2022-2032

• 8.1. North America Metabolomics Technologies Market
  • 8.1.1. U.S. Metabolomics Technologies Market
    • 8.1.1.1. Product breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Indication breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Application breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Metabolomics Technologies Market
• 8.2. Europe Metabolomics Technologies Market
  • 8.2.1. UK Metabolomics Technologies Market
  • 8.2.2. Germany Metabolomics Technologies Market
  • 8.2.3. France Metabolomics Technologies Market
  • 8.2.4. Spain Metabolomics Technologies Market
  • 8.2.5. Italy Metabolomics Technologies Market
  • 8.2.6. Rest of Europe Metabolomics Technologies Market
• 8.3. Asia-Pacific Metabolomics Technologies Market
  • 8.3.1. China Metabolomics Technologies Market
  • 8.3.2. India Metabolomics Technologies Market
  • 8.3.3. Japan Metabolomics Technologies Market
  • 8.3.4. Australia Metabolomics Technologies Market
  • 8.3.5. South Korea Metabolomics Technologies Market
  • 8.3.6. Rest of Asia Pacific Metabolomics Technologies Market
• 8.4. Latin America Metabolomics Technologies Market
  • 8.4.1. Brazil Metabolomics Technologies Market
  • 8.4.2. Mexico Metabolomics Technologies Market
  • 8.4.3. Rest of Latin America Metabolomics Technologies Market
• 8.5. Middle East & Africa Metabolomics Technologies Market
  • 8.5.1. Saudi Arabia Metabolomics Technologies Market
  • 8.5.2. South Africa Metabolomics Technologies Market
  • 8.5.3. Rest of Middle East & Africa Metabolomics Technologies Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Agilent Technologies Inc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Bio-Rad Laboratories Inc.
  • 9.3.3. Bruker
  • 9.3.4. Danaher Corp.
  • 9.3.5. Merck KGaA
  • 9.3.6. Shimadzu Corp.
  • 9.3.7. Thermo Fisher Scientific Inc.
  • 9.3.8. Waters Corp.
  • 9.3.9. Biocrates Life Sciences AG
  • 9.3.10. Creative Proteomics
  • 9.3.11. Owl Metabolomics
  • 9.3.12. Metabolomic Discoveries GmbH
  • 9.3.13. Numares AG
    • 9.3.1.4. Metabolon, Inc.
  • 9.3.15. Chenomx Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes